Researchers concluded that there has been significant expansion of coverage for ctDNA assays over the past four years, but policies remain very heterogeneous and often limited.
The company expects to garner clearance for its platform in the US first for Lynch syndrome as it builds additional evidence for an immunotherapy application.
The company enters a race to the clinic with several direct competitors, including Guardant Health and CellMax Life, as well as other firms pursuing multi-cancer screening.
The firm is planning a hybrid approach to clinical translation, including launching some of its own cancer tests and licensing technology to other labs.
The firm has collected important health economic evidence for its clinical lung cancer assay and is building evidence for other products in additional cancer types.
The company is creating a high-throughput NGS test for healthcare workers and the underserved, and to support viral surveillance programs for large employers.
A study of both tissue and blood samples from patients in a small trial found that liquid biopsy may detect putative resistance mutations missed in tissue.
